Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

RSPI Relative to the S&P 500

RSPI Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the RespireRx Pharmaceuticals Inc. (OTCMKT:RSPI) seasonal charts above shows that a Buy Date of December 30 and a Sell Date of March 22 has resulted in a geometric average return of 35.55% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 18 of those periods. This is an excellent rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 72.45% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

RespireRx Pharmaceuticals Inc is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The pipeline products of the company are dronabinol which is developed for the treatment of OSA (Obstructive Sleep Apnea), a form of sleep apnea; CX1739 for the treatment of chronic central sleep apnea; CX717 and CX1942 is an injectable dosage for respiratory depression or vaso-occlusive passes associated with sickle cell disease. It also focuses on developing another class of compounds called ampakines for the treatment of various respiratory disorders.

To download RSPI seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: RSPI